ABSTRACT
Cleaning and saving the forest is related to managing and utilizing forests' biodiversity, productivity, and considering the relevant environment. Plastic waste management is now seen as an important goal for sustainable forest use as well as incorporating recycled plastics into products. Another way that industries impact wildlife and forests is by releasing additives such as industrial gases, organic & inorganics materials, plastic & resins, fertilizers & alkalies, and chlorine. Polymer wastes manage to enter into and harm numerous biological functions of animals. In this work, the concept of sustainable Türkiye's forest practices and addressing the impact of plastic waste on the forests and environment before and during the COVID-19 epidemic are discussed along with current sources of those mentioned materials wastes that manage to enter the environment. Through this work, the data of bio thermochemistry and thermodynamics calculations of such polymers have been investigated to exhibit the range of sustainability and unsustainability of those mentioned polymers and resins in the environment due to forest climate change. Since the Türkiye chemical industry is one of the most important industrial factors, their production contributes in similar proportions to greenhouse gas emissions. Interestingly, low data on energy usage in the factories and chemical industry is available in the public domain. Ethylene production is the major product in terms of the production volume of the petrochemical industry. Nitrogenous fertilizer production is a very energy-intensive industry, producing a variety of fertilizers and other nitrogen compounds. In addition, ammonia, chlorine, and caustic soda are the most important mediator chemical material used as the main compound for almost all products. © 2023 by the authors.
ABSTRACT
Background: Chronic urticaria (CU) is a common chronic inflammatory disease. Vaccination against viral infections including COVID-19 can induce increased CU disease activity. As of now, it is unclear how often CU exacerbations occur after COVID-19 vaccination. Method(s): COVAC-CU is an international, multicenter, observational, cross-sectional study of the global network of urticaria centers of reference and excellence (UCAREs). COVAC-CU evaluates the effects of COVID-19 vaccination in patients with CU including rates and risk factors of CU exacerbation. Here, we analyzed 1857 patients with CU who had received at least one COVID-19 vaccination. Data were collected via a questionnaire and retrieved from patient charts. Result(s): Of 1857 patients with CU (median age: 42 years;range: 18-91 years), 72.1% were female and 71.2%, 14.4% and 14.4% had chronic spontaneous urticaria, chronic inducible urticaria, or both, respectively. Most patients had received two doses of COVID-19 vaccine (79.1%), compared to one (9.7%), three (11%), or four (0.3%). Vaccine type included: BTN162b2 (58.4%;BioNTech/Pfizer), ChAdOx1 nCOV-19 (13.8%;AstraZeneca), BBIBP-CorV (8.2%;Sinopharm), Gam-COVID- Vac (8%;Sputnik), mRNA-1273 (5.3%;Moderna), and Ad26.COV 2.5 (4.7%;Janssen/J&J). Less than 10% of patients used premedication, and less than half of patients (44.4%) reported one or more adverse reactions after vaccination. The most common adverse reactions were local injection site reactions (29.6%), fatigue (19.7%), fever (19%), muscle pain (17.9%), headache (14%), and exacerbation of CU (15%). Severe allergic reactions/anaphylaxis were reported by 0.4% of CU patients. In almost all patients who experienced exacerbation of their CU, this occurred within one week after receiving the vaccine, i.e. after 1 to 12 hours (25.8 %), after 12 hours to 48 hours (31.1%) or after 2-7 days (37.9%). Conclusion(s): Most CU patients tolerate COVID-19 vaccination well;severe allergic reaction (anaphylaxis) rates were similar or lower than the self-reported rates reported in the general population. Exacerbation of urticaria was reported in one in five patients, mostly in a week after receiving the vaccine.
ABSTRACT
The effect of COVID-19 vaccination also depends on the population that accepts vaccines. Improving the COVID-19 vaccination methods will be tremendous to human health and the world economy. So, in this work, we use an interdisciplinary knowledge from climates, social sciences, geography, jungle, forestry and wood industry, genetic analysis, and computational biophysics, including artificial intelligence and docking simulation. The emergence of the omicron variant raises serious concerns because of the initial observation of a significant growth advantage compared to the Delta, lambda, beta, and gamma variants. Although the omicron variant preliminary observed in the EU/EEA and Asian countries depend on travel, several are now observed as parts of pandemic clustering in this zoon. Since, even if the severity of the disease is lower compared with other variants, particularly Delta, the fast transmissibility and resulting exponential growth of cases will soon outweigh any benefits of a potentially reduced severity. This research showed that though omicron covid-19 death cases are less severe than Delta, Omicron will be an important base for the emergence of new further variants through huge mutations in the future, which some are so dangerous. Due to the wet climate, the Amazon jungle is a suitable substrate for emerging any further corona variants. © 2022 by the authors.
ABSTRACT
Background: Cabozantinib is a small molecule inhibitor of the tyrosine kinases c-Met, AXL and VEGFR2 that has been shown to reduce tumor growth, metastasis, and angiogenesis. After the promising results from the METEOR, CABOSUN and Checkmate-9ER trials, cabozantinib was approved for use in patients with advanced renal cell carcinoma (RCC). The increased response rates with cabozantinib in metastatic RCC, along with the other neoadjuvant TKI data, support an expanded role for cabozantinib in the neoadjuvant setting. Methods: Patients with clinical stage ≥ T3Nx or TanyN+ or deemed unresectable by the surgeon with biopsy-proven clear cell RCC were eligible for this study, and received cabozantinib at a starting dose of 60 mg daily for 12 weeks. The primary outcome was objective response rate per RECIST v1.1 (complete and partial responses) at week 12 after the administration of cabozantinib as determined by independent radiologist review. Secondary outcomes included safety, tolerability, clinical outcome (DFS, OS), surgical outcome and quality of life. Results: As of 20 September 2021, 16 biopsy-proven clear cell RCC patients were treated with neoadjuvant cabozantinib. The median age was 56 years (range: 41-84 years) and 81.2% male. All patients completed 12 weeks of treatment, and 15 of them underwent surgery as planned without any delay after completion of 4 weeks wash-out. One patient refused to undergo surgery due to personal reasons and received further systemic treatment. Five patients (31.2%) experienced a partial response, and 11 patients had stable disease. There was no progression of disease while on cabozantinib. Median reduction of primary renal tumor size was 24% (range: 6-45%). The one patient who was deemed to be unresectable became resectable at the end of treatment. Two patients were converted from radical to partial nephrectomy. The most common AEs were diarrhea, nausea, fatigue, hypertension, anorexia, and palmar-plantar erythrodysesthesia syndrome. Intraoperatively, we did not experience any immediate complications. Postoperatively, no surgical complications related to the drug were noted. No treatment related grade 4 or 5 AEs related to cabozantinib or surgery occurred. Two patients had died at the time of analysis (1 due to COVID and 1 unknown cause). Conclusions: Cabozantinib was clinically active and safe in the neoadjuvant setting in patients with locally advanced non-metastatic clear cell RCC. Additional data will be reported including long term outcomes, correlative studies, quality of life, and frailty/sarcopenia indices.
ABSTRACT
There is no standard practice for the sustainability of medical education in epidemics such as Covid-19 and disasters affecting society. Synchronous or asynchronous trainings have been carried out in some of universities and colleges that have distance education technical infrastructure, during the Covid-19 pandemic. If every student has access to information technologies and the skills of the instructors who will prepare and deliver the training increase their ability to use information technologies, there is no problem in the implementation and maintenance of theoretical lessons. During the Covid-19 pandemic, we had to go to distance education, which we had not yet implemented at Bezmialem Vakif University Faculty of Medicine. During this period, we applied asynchronous and synchronous education models (mixed model) for theoretical lessons. However, the fact that practical and internship applications were carried out by distance education - although videos about skills and practices were shot and uploaded to the system - it was not possible to replace the formal education. Distance education is inevitable for the continuity of education in epidemic and disaster situations. However, after the epidemic and disaster situations have passed, practical and internship practices should be carried out as much as possible in addition to distance education in medical education. In normal times, distance education can only be used to support formal education in medical education. As a result of all these evaluations and experiences we gained in the Covid 19 pandemic, we think that synchronous/synchronous distance education applications will improve over time and contribute to medical education.